Time for process excellence in Pharma R&D?



Diana Davis
12/14/2012

For years pharmaceutical companies could rake in high margins on drugs that were protected by patents. But as many patents have expired or are near expiration – so much so that the industry is calling it the "patent cliff" – pharma companies are having to look much harder at how they can streamline processes in R&D to save time and money. In this Process Perspectives podcast, Andrew Parson, VP Preclinical Drug Development at GlaxoSmithKline and Gerald Fincken, CEO of CSM Clinical...
TO READ THE FULL STORY